Cancer Treatment Indications Quiz

Cancer Treatment Indications

• Melanoma (unresecable/metastatic): Adjuvant treatment options exist.
• Non-Small Cell Lung Cancer (NSCLC): Single-agent therapy for localized and advanced disease. Combination therapy for resectable and metastatic disease.
• Head & Neck Squamous Cell Carcinoma: Single-agent and combination therapies available.
• Classical Hodgkin Lymphoma (cHL): Indicated for relapsed or refractory cHL. Dose: 200 mg IV q3Weeks or 400 mg q6Weeks until disease progression, unacceptable toxicity, or 24 months without progression.

Lymphoma Treatment

• Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Indicated for refractory or relapsed (after ≥2 prior lines of therapy) PMBCL. Same dosage as cHL (200 mg IV q3Weeks, or 400 mg q6Weeks).
• Different dosages for various cancer types: Dosages and schedules vary based on the specific cancer type.

Other Cancer Indications

• Urothelial Carcinoma: Single-agent or combination therapy (with enfortumab) is an option.
• Microsatellite Instability-High (MSI-H)/Mismatch Repair Deficient (dMMR) Cancers: 200 mg IV q3Weeks or 400 mg q6Weeks until progression, unacceptable toxicity, or 24 months without progression. Targets solid tumors that have progressed after prior treatment.
• Colorectal Cancer (MSI-H/dMMR): 200 mg IV q3Weeks or 400 mg IV q6Weeks until disease progression, unacceptable toxicity, or 24 months.
• Gastric Cancer (HER2-positive): Combination therapy with trastuzumab, fluoropyrimidine-, and platinum-containing chemotherapy indicated for first-line treatment.
• Gastric Cancer (HER2-negative): Same combination therapy as above, but for HER2-negative gastric/GEJ adenocarcinoma.
• Esophageal Cancer: Indicated for treating recurrent locally advanced or metastatic esophageal/GEJ carcinoma in patients ineligible for surgery or radiation.
• Cervical Cancer: Available as single-agent, combination chemotherapy, or combination chemoradiotherapy.
• Hepatocellular Carcinoma (HCC): Indicated for patients with hepatitis B-related HCC who have received prior systemic therapy (except regimens containing PD-1/PD-L1 inhibitors); Same dosage as above.
• Merkel Cell Carcinoma (MCC): Indicated for recurrent, locally advanced, or metastatic MCC. Dosage same as above.
• Renal Cell Carcinoma (RCC): Available in combination with axitinib or lenvatinib as combination therapy, and may have adjuvant treatment options.
• Endometrial Cancer: Combination therapy with lenvatinib and carboplatin/paclitaxel are options. Can also be a single agent treatment.
• Tumor Mutational Burden-High (TMB-H) Cancers (≥10 mutations/megabase [mut/Mb]): 200 mg IV q3Weeks or 400 mg q6Weeks until progression, unacceptable toxicity, or 24 months without progression. Targets solid tumors that have progressed following prior treatment.
• Cutaneous Squamous Cell Carcinoma (cSCC): For recurrent/metastatic cSCC or locally advanced cSCC incurable by surgery or radiation; same dosage scheme.
• Breast Cancer (High-risk early-stage TNBC and Locally recurrent unresectable or metastatic TNBC): Treatment options exist for both.
• Biliary Tract Cancer (BTC): Combination therapy with gemcitabine and cisplatin is an option. Administered before chemotherapy when given on the same day.

Important Notes

• Specific dosages, schedules, and durations of treatment should be confirmed with a healthcare professional for optimal management.
• These notes do not constitute medical advice.
• Conditions and treatment vary greatly among patients.

Test your knowledge on various cancer treatment indications including melanoma, lung cancer, and lymphoma. This quiz covers both single-agent and combination therapies, as well as specific dosage recommendations for different cancer types. Perfect for students and professionals in oncology!